// App-Quantinova.ai

283 : Testing a prognostic model in patients with metastatic castrate resistant prostate cancer (MCRPC) treated prechemotherapy with abiraterone.

Researchers

Presenter

  • Shermaine Pan

Principal Investigators

  • Kellati Prasad

  • Emma Hall

  • Ric Swindell

  • Natalie Charnley

Medical Centers

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Royal Wolverhampton Hospital, Wolverhampton, United KingdomRosemere Centre, Royal Preston Hospital, Preston, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved